Literature DB >> 21112136

Brachial artery conductance during reactive hyperemia is increased in women with polycystic ovary syndrome.

Nazia Raja-Khan1, Showieb A Shuja, Allen R Kunselman, Cynthia S Hogeman, Laurence M Demers, Carol L Gnatuk, Richard S Legro.   

Abstract

OBJECTIVE: To examine changes in brachial artery conductance (BAC) during reactive hyperemia in women with polycystic ovary syndrome (PCOS) compared to controls. STUDY
DESIGN: This is a pilot case-control study performed at a single academic medical center. Changes in BAC during reactive hyperemia were evaluated in 31 women with PCOS and 11 healthy control women. Fasting glucose, insulin, lipids and androgen levels were also determined. A mixed-effects model was used to compare the PCOS curve to the control curve for change in BAC from baseline during reactive hyperemia.
RESULTS: Body mass index (BMI) and testosterone levels were significantly increased in the PCOS group compared to controls (P<0.05). In addition, the PCOS group had higher total and LDL cholesterol levels (P=0.05 and 0.09, respectively). Change in BAC from baseline during reactive hyperemia was significantly increased in the PCOS group compared to controls even after adjusting for age, BMI and LDL cholesterol levels (P<0.0001). There were no significant differences between the two groups in age, blood pressure, or fasting glucose or insulin levels.
CONCLUSIONS: Brachial artery conductance during reactive hyperemia is significantly increased in women with PCOS compared to controls and may be a novel early indicator of increased cardiovascular risk in women with PCOS.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112136      PMCID: PMC3046318          DOI: 10.1016/j.ejogrb.2010.10.027

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  33 in total

1.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.

Authors:  R S Legro; A R Kunselman; A Dunaif
Journal:  Am J Med       Date:  2001-12-01       Impact factor: 4.965

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance.

Authors:  Erica B Johnstone; Mitchell P Rosen; Rebecca Neril; Deborah Trevithick; Barbara Sternfeld; Rosemary Murphy; Carolyne Addauan-Andersen; Daniel McConnell; Renee Reijo Pera; Marcelle I Cedars
Journal:  J Clin Endocrinol Metab       Date:  2010-08-18       Impact factor: 5.958

4.  Hirsutism: implications, etiology, and management.

Authors:  R Hatch; R L Rosenfield; M H Kim; D Tredway
Journal:  Am J Obstet Gynecol       Date:  1981-08-01       Impact factor: 8.661

5.  Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.

Authors:  Francesco Orio; Stefano Palomba; Teresa Cascella; Biagio De Simone; Sebastiano Di Biase; Tiziana Russo; Donato Labella; Fulvio Zullo; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

Review 6.  Role of endothelial dysfunction in atherosclerosis.

Authors:  Jean Davignon; Peter Ganz
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

7.  Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study.

Authors:  Emelia J Benjamin; Martin G Larson; Michelle J Keyes; Gary F Mitchell; Ramachandran S Vasan; John F Keaney; Birgitta T Lehman; Shuxia Fan; Ewa Osypiuk; Joseph A Vita
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

Review 8.  Ultrasound assessment of the polycystic ovary: international consensus definitions.

Authors:  Adam H Balen; Joop S E Laven; Seang-Lin Tan; Didier Dewailly
Journal:  Hum Reprod Update       Date:  2003 Nov-Dec       Impact factor: 15.610

9.  Forearm reactive hyperemia and mortality in end-stage renal disease.

Authors:  Gérard M London; Bruno Pannier; Mohsen Agharazii; Alain P Guerin; Francis H M Verbeke; Sylvain J Marchais
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

10.  Polycystic ovaries--a common finding in normal women.

Authors:  D W Polson; J Adams; J Wadsworth; S Franks
Journal:  Lancet       Date:  1988-04-16       Impact factor: 79.321

View more
  5 in total

1.  High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial.

Authors:  Nazia Raja-Khan; Julie Shah; Christy M Stetter; Mary E J Lott; Allen R Kunselman; William C Dodson; Richard S Legro
Journal:  Fertil Steril       Date:  2014-03-14       Impact factor: 7.329

Review 2.  The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Elisabet Stener-Victorin; XiaoKe Wu; Richard S Legro
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-12       Impact factor: 4.310

3.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

4.  Endothelin B receptor contribution to peripheral microvascular function in women with polycystic ovary syndrome.

Authors:  Megan M Wenner; Hugh S Taylor; Nina S Stachenfeld
Journal:  J Physiol       Date:  2011-08-08       Impact factor: 5.182

5.  Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.

Authors:  Nazia Raja-Khan; Allen R Kunselman; Cynthia S Hogeman; Christy M Stetter; Laurence M Demers; Richard S Legro
Journal:  Fertil Steril       Date:  2010-12-08       Impact factor: 7.329

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.